Leen et al (39) conducted a study on 57 patients with GLUT1-DS, and found that the KD was effective in 86% of the patients with epilepsy, and significantly reduced movement disorder in 48% of the patients with classical phenotype and 71% of the patients with non-classical phenotype. This evidence concerns the gene SLC2A1 and movement disorder.